Compare Organon & Co. Common Stock (OGN) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Koninklijke Philips NV — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Koninklijke Philips NV trades at $25.28 (market cap $24.24B). The key difference: Koninklijke Philips NV is far larger — about 6.7× Organon & Co. Common Stock's market cap, and Koninklijke Philips NV pays the higher dividend (4.07%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Koninklijke Philips NV for 84 Days on average.
| OGN | PHG | |
|---|---|---|
Market Cap | $3.62B | $24.24B |
Volume | 2,892,999 | 982,766 |
Sector | Health | Health |
52-Week High | $13.81 | $32.91 |
52-Week Low | $5.70 | $23.81 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $11.04B | $30.57B |
Dividend Yield | 0.58% | 4.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PHG trades at $25.00, up 1.05% today, with a bullish technical signal despite mixed oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.57 exceeding the $0.40 estimate. Revenue for 2025 was $17.83 billion, with a net income margin of 5.01%, showing a recovery from prior losses. Recent news highlights product launches and strategic partnerships in healthcare technology.
The outlook is cautiously optimistic, supported by earnings momentum and innovation, but risks include competitive pressures and debt levels. Analysts are mixed, with a 'Hold' consensus, while institutional buying activity indicates underlying confidence. Valuation metrics like a P/E of 19.49 suggest the stock is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
